Cleo Diagnostics Sets U.S. Reimbursement Stage Ahead of FDA Nod

Early U.S. Commercialisation Strategy Unveiled

Cleo Diagnostics (ASX:COV) has mapped out its U.S. market launch playbook for its Pre-Surgical Ovarian Cancer Test, aiming to hit the ground running immediately after FDA clearance. The company will commercialise the test under the miscellaneous CPT code 81599, a catch-all billing code for novel diagnostics, allowing it to start generating revenue and real-world usage data without waiting for a dedicated reimbursement code.

This approach is a pragmatic move to accelerate clinical adoption and provide payers with early evidence of the test’s value. The reimbursement under this code is negotiated payer-by-payer, typically referencing similar multi-biomarker ovarian cancer assays such as OVA1, which reportedly command reimbursement rates between US$500 and US$900 per test. This range provides a tangible benchmark for Cleo’s pricing discussions as it prepares to enter the competitive U.S. diagnostics landscape.

Launching under CPT code 81599 also enables Cleo to build the clinical and economic data necessary to support a future application for a dedicated CPT code through the American Medical Association’s CPT Editorial Panel. Securing a dedicated code would bring standardised reimbursement, broader payer coverage, and greater commercial stability, crucial for scaling the test’s adoption across U.S. healthcare providers.

Supporting Market Access with Evidence and Advocacy

Beyond reimbursement mechanics, Cleo is actively advancing its market access strategy by developing health economics models and engaging key opinion leaders to champion early clinical uptake. These efforts complement its ongoing pivotal clinical trial, which recently completed recruitment with over 500 samples collected, and its manufacturing ramp-up with Bio-Techne, positioning the company for a seamless transition from trial to commercial launch. The clinical trial progress and manufacturing updates were detailed in recent reports highlighting milestones in sample collection and assay development pivotal trial recruitment and manufacturing program with Bio-Techne.

Generating real-world evidence through initial commercial rollout will be critical to demonstrating the test’s clinical utility and economic impact, reinforcing its value proposition to payers and providers. This data-driven approach is designed to smooth the path toward a dedicated CPT code and broader reimbursement acceptance.

Timeline to Dedicated CPT Code and Commercial Scale

Cleo’s reimbursement timeline is staged: immediate post-FDA clearance commercialisation under CPT 81599, followed by a CPT application submission after 6 to 12 months of real-world utilisation, and eventual assignment of a dedicated CPT code. This phased strategy balances the urgency of market entry with the regulatory and payer requirements needed for sustainable reimbursement.

While the FDA clearance date remains forthcoming, Cleo’s proactive reimbursement groundwork positions it well to capitalise on the commercial opportunity once regulatory green lights are received. The company’s focus on early billing, clinical adoption, and evidence generation reflects a nuanced understanding of the U.S. diagnostics market’s reimbursement complexities.